

FDA-AACR Non-clinical Models for Safety Assessment of Immuno-oncology Products Workshop September 6, 2018 | Washington, DC

Workshop Cochairs:

John K. Leighton, PhD, Director, Division of Hematology Oncology Toxicology, Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Haleh Saber, PhD, Deputy Director, Division of Hematology Oncology Toxicology, Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Julie Schneider, PhD, Regulatory Scientist, Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

	AGENDA
8:00 AM	Welcome and Workshop Objectives
	John K. Leighton, PhD, U.S. Food and Drug Administration
8:15 AM	Current Non-clinical Models for Immuno-oncology Products
	Marcela V. Maus, MD, PhD, Harvard Medical School, Massachusetts General Hospital
8:45 AM	Experience with Keytruda/MM and Use of Animal Models Sarah Javaid, PhD, Merck
9:15 AM	Humanized Mice
	Karolina Palucka, MD, PhD, The Jackson Laboratory for Genomic Medicine
10:00 AM	BREAK
10:15 AM	Evaluating IO Toxicities in Syngeneic Immunocompetent Mouse Models: Lessons, Opportunities and Challenges
	Gregory L. Beatty, MD, PhD, University of Pennsylvania Perelman School of Medicine
11:00 AM	A Comparative Approach to Immuno-oncology Drug Development: Integration of Companion Canine Models
	Amy K. LeBlanc, DVM, National Cancer Institute
11:50 AM	LUNCH BREAK (ON YOUR OWN)
1:00 PM	Challenges and Opportunities in Developing Non-clinical Models for Immuno-oncology
	Lei Zheng, MD, PhD, Johns Hopkins University School of Medicine, Sidney Kimmel Cancer Center
1:45 PM	PANEL DISCUSSION
Moderator:	Haleh Saber, PhD, FDA
Panelists:	Gregory L. Beatty, MD, PhD, University of Pennsylvania Perelman School of Medicine Sarah Javaid, PhD, Merck
	Marcela V. Maus, MD, PhD, Harvard Medical School, Massachusetts General Hospital
	Karolina Palucka, MD, PhD, The Jackson Laboratory for Genomic Medicine
	Lei Zheng, MD, PhD, Johns Hopkins University School of Medicine, Sidney Kimmel Cancer Center

2:15 PM Animal Models in Immuno-oncology Drug Development

Danuta Herzyk, PhD, Merck

2:50 PM Use of Antigen Challenge in Non-human Primate to Assess Pharmacodynamic Activity and Translation

to Clinic

Helen Haggerty, PhD, Bristol-Myers Squibb

3:15 PM BREAK

3:25 PM A Case Study of Mitigating Safety Risk for Combination Therapy of IO Biologics and Small Molecules

Robert Li, PhD, DABT, Genentech

3:40 PM NCI Funding Programs That Support Development of Cancer Models

Mariam Eljanne, PhD, National Cancer Institute

3:55 PM PANEL DISCUSSION and AUDIENCE Q&A

Moderators: John K. Leighton, PhD, and Julie Schneider, PhD, FDA

Panelists: Mariam Eljanne, PhD, National Cancer Institute

Helen Haggerty, PhD, Bristol-Myers Squibb

Danuta Herzyk, PhD, Merck

Alan Korman, PhD, Bristol-Myers Squibb

Robert Li, PhD, DABT, Genentech

4:40 PM ADJOURN